Compare iShares MBS ETF (MBB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Sanofi SA — how do they compare? iShares MBS ETF trades at $89.7 (market cap $35.41B), while Sanofi SA trades at $40.02 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 2.7× iShares MBS ETF's market cap, and Sanofi SA pays a 6.01% dividend while iShares MBS ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and Sanofi SA for 94 Days on average.
| MBB | SNY | |
|---|---|---|
Market Cap | $35.41B | $95.18B |
Volume | 5,388,525 | 2,995,646 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $52.34 |
52-Week Low | $89.09 | $39.51 |
Typical Hold Time | 96 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB (iShares MBS ETF) trades at $89.22, down 0.16% amid bearish technical signals with 18 sell indicators versus 2 buy signals. The ETF faces pressure from rising intermediate-term rates and inflation concerns, with short interest surging 98.3% in September 2026 to 6.57 million shares. Recent institutional activity shows mixed sentiment with some firms increasing positions while technical indicators point to continued downward momentum.
The outlook remains challenging with convexity risk and borrower prepayment optionality limiting upside potential. Investment opportunity exists for income-focused investors through consistent dividend payments, but risks include duration exposure during potential rate hikes and persistent inflation pressures affecting mortgage-backed securities performance.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
